BCYC

Bicycle Therapeutics plc - ADR (BCYC) | Rumor.io

Bicycle Therapeutics

BCYC

Attention (50-day avg)0%

Attention rank (50-day avg)#3,598

Bullish sentiment (50-day avg)75%

Price to earnings ratio-1.17

Market capitalization259M

Earnings per share-2.73

Dividend yield (TTM)—

Revenue (annual)72.6M

Net income (annual)-219M

Social

What share of all stock conversation is about BCYC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Mar 24

Bicycle Therapeutics plc ($BCYC) has a catalyst event on April 19, 2026, presenting human trial data on its lead drug at a major cancer conference, which could lead to a strong stock reaction.
The company has a strong cash position with $628 million as of December 31, 2025, and has extended its runway into 2030 due to recent layoffs.
The company's focus has shifted to BT5528/nuzefatide, with near-term data expected in H1 2026, and a longer-term bet on their radioconjugate platform, which could lead to a breakout.

Generated by AI

Sentiment

Of the messages about BCYC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	50% -50	53.76% -2.32
Bearish	—	—	50% new	46.24% +2.32

Oct 8

$BCYC's price target was raised to $76 by Piper Sandler, with an overweight rating.
Bicycle Therapeutics' cancer study data drew higher price targets from analysts, including a $65 PT from Oppenheimer and a $65 PT from HC Wainwright.
$BCYC's stock price surged 24.12% since the buy alert, with the stock reaching a new high of $53.78.

Generated by AI

Topics

Of the messages about BCYC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	80%	37.88%
Analysts	—	0%	0%	32.83%
Macro	—	0%	20%	27.78%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Technical Analysis	—	0%	0%	1.52%

Aug 18

Bicycle Therapeutics plc (BCYC) is a UK-based pharma company with a focus on precision-guided therapeutics for cancer treatment.
BCYC has a strong balance sheet with $918m net cash, after subtracting debt, and is valued at $1.55 billion.
The company has a drug in the pipeline, BT8009 (also known as Zelenectide pevedotin), which is a crucial part of its development efforts.

Generated by AI

Community

Of the messages about BCYC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	30%	41.56%
Newcomers	—	0%	70%	58.44%

Regulars· May 4

Bicycle Therapeutics has announced a collaboration with the German Cancer Research Center to discover and develop wholly owned Bicycle(R) radio conjugates for various oncology targets.
The company has reported its first quarter 2023 financial results, which show a revenue growth rate of -15.50% YoY, ranking 3533 out of 5755 companies in the database.
Bicycle Therapeutics is scheduled to release its earnings on Friday, with some speculating that the price may drop due to a potential breach of the higher Bollinger Band.

Newcomers· Apr 11

Newcomers to discussing Bicycle Therapeutics plc are focusing on the company's neuropathy rate, comparing it to that of Padcev and highlighting the potential for a rash of neutropenia.
The reaction to Bicycle Therapeutics plc's stock price is surprising to some, with some attributing it to a lack of attention to the company's platform capabilities and its validation through a successful market listing.
Newcomers are taking a bullish view on Bicycle Therapeutics plc, impressed by its AACR presentation and planning to build a long-term position in the company through small batches on pullbacks.

Generated by AI

News

Bicycle Therapeutics Announces Board and Advisory Resignation

Detailed price information for Bicycle Therapeutics Plc ADR (BCYC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

Detailed price information for 60 Degrees Pharmaceuticals Inc (SXTP-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Bicycle: 'Hold' On Zelenectide Deprioritization And Shift To EphA2+ Tumor Targeting

1mo agoSeeking Alpha

RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

Detailed price information for Bicycle Therapeutics Plc ADR (BCYC-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)

Detailed price information for Bicycle Therapeutics Plc ADR (BCYC-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

2mo agotheglobeandmail.com

Also Discussed

Investors talking about BCYC also mention

#	Name	Attention
1	ALX Oncology Holdings Inc.ALXO	0%0
2	IGMS - IGM Biosciences, Inc.	——
3	IDEAYA Biosciences Inc.IDYA	0%-0.01
4	RPTX - Repare Therapeutics Inc.	——
5	Kymera Therapeutics Inc.KYMR	0%0
6	SWTX - SpringWorks Therapeutics, Inc.	——
7	Kura Oncology, Inc.KURA	0%+0
8	Immatics N.V.IMTX	0%0
9	Zymeworks Inc.ZYME	0%0
10	PMV Pharmaceuticals, Inc.PMVP	0%0

Bicycle Therapeutics plc - ADR

Healthcare
Biotechnology

Bicycle Therapeutics plc - ADR is a clinical-stage biopharmaceutical company focused on developing a novel class of medicines known as Bicycle molecules. The company applies its proprietary bicyclic peptide platform to create targeted therapies designed to address diseases that are underserved by existing treatments, with a primary emphasis on oncology and other serious conditions. Its current pipeline includes Bicycle toxin conjugates and related precision medicine programs that are being evaluated in clinical trials for tumor types and other disease areas. Bicycle Therapeutics also works with partners to extend its technology into additional therapeutic applications, including radiopharmaceutical and non-oncology research. Based in Cambridge, United Kingdom, Bicycle Therapeutics plc - ADR plays a specialized role in the biotechnology market by advancing highly selective drug candidates that combine small-molecule-like properties with peptide-based targeting.

Website

Location

Portway Building

Cambridge, CB21 6GS

United Kingdom

Social

What share of all stock conversation is about BCYC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Mar 24

Bicycle Therapeutics plc ($BCYC) has a catalyst event on April 19, 2026, presenting human trial data on its lead drug at a major cancer conference, which could lead to a strong stock reaction.
The company has a strong cash position with $628 million as of December 31, 2025, and has extended its runway into 2030 due to recent layoffs.
The company's focus has shifted to BT5528/nuzefatide, with near-term data expected in H1 2026, and a longer-term bet on their radioconjugate platform, which could lead to a breakout.

Generated by AI

Sentiment

Of the messages about BCYC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	50% -50	53.76% -2.32
Bearish	—	—	50% new	46.24% +2.32

Oct 8

$BCYC's price target was raised to $76 by Piper Sandler, with an overweight rating.
Bicycle Therapeutics' cancer study data drew higher price targets from analysts, including a $65 PT from Oppenheimer and a $65 PT from HC Wainwright.
$BCYC's stock price surged 24.12% since the buy alert, with the stock reaching a new high of $53.78.

Generated by AI

Topics

Of the messages about BCYC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	80%	37.88%
Analysts	—	0%	0%	32.83%
Macro	—	0%	20%	27.78%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Technical Analysis	—	0%	0%	1.52%

Aug 18

Bicycle Therapeutics plc (BCYC) is a UK-based pharma company with a focus on precision-guided therapeutics for cancer treatment.
BCYC has a strong balance sheet with $918m net cash, after subtracting debt, and is valued at $1.55 billion.
The company has a drug in the pipeline, BT8009 (also known as Zelenectide pevedotin), which is a crucial part of its development efforts.

Generated by AI

Community

Of the messages about BCYC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	30%	41.56%
Newcomers	—	0%	70%	58.44%

Regulars· May 4

Bicycle Therapeutics has announced a collaboration with the German Cancer Research Center to discover and develop wholly owned Bicycle(R) radio conjugates for various oncology targets.
The company has reported its first quarter 2023 financial results, which show a revenue growth rate of -15.50% YoY, ranking 3533 out of 5755 companies in the database.
Bicycle Therapeutics is scheduled to release its earnings on Friday, with some speculating that the price may drop due to a potential breach of the higher Bollinger Band.

Newcomers· Apr 11

Newcomers to discussing Bicycle Therapeutics plc are focusing on the company's neuropathy rate, comparing it to that of Padcev and highlighting the potential for a rash of neutropenia.
The reaction to Bicycle Therapeutics plc's stock price is surprising to some, with some attributing it to a lack of attention to the company's platform capabilities and its validation through a successful market listing.
Newcomers are taking a bullish view on Bicycle Therapeutics plc, impressed by its AACR presentation and planning to build a long-term position in the company through small batches on pullbacks.

Generated by AI

Bicycle Therapeutics

Social

Mar 24

Oct 8

Aug 18

Regulars· May 4

Newcomers· Apr 11

Bicycle Therapeutics Announces Board and Advisory Resignation

Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

Bicycle: 'Hold' On Zelenectide Deprioritization And Shift To EphA2+ Tumor Targeting

RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

Also Discussed

Bicycle Therapeutics plc - ADR

Company Information

Location

Bicycle Therapeutics Announces Board and Advisory Resignation

Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

Bicycle: 'Hold' On Zelenectide Deprioritization And Shift To EphA2+ Tumor Targeting

RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)

Truist Financial Remains a Hold on Bicycle Therapeutics (BCYC)

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Alnylam Pharma (ALNY) and Fortrea Holdings Inc. (FTRE)

Also Discussed

Social

Mar 24

Oct 8

Aug 18

Regulars· May 4

Newcomers· Apr 11